Evidence map›Paper›PMID 41926020›Full record

ArticleInternational journal of hematology2026

Are matched-related donors always the best choice? A retrospective study exploring the potential of umbilical cord blood.

Nobuhiko Imahashi, Takaaki Konuma, Shinichi Kobayashi, Mizuki Watanabe, Satoshi Takahashi, Tetsuya Nishida, Toshiro Kawakita, Hirohisa Nakamae, Noriko Doki, Yasushi Onishi and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nobuhiko ImahashiDepartment of Hematology, NHO Nagoya Medical Center, 4-1-1Naka-Ku, SannomaruNagoya, Aichi, 460-0001, Japan. imahashi.nobuhiko.wf@mail.hosp.go.jp.ORCID http://orcid.org/0000-0002-1398-2002
Takaaki KonumaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shinichi KobayashiDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
Mizuki WatanabeDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Satoshi TakahashiDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tetsuya NishidaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Toshiro KawakitaDepartment of Hematology, NHO Kumamoto Medical Center, Kumamoto, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Yasushi OnishiDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Mamiko Sakata-YanagimotoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Noriyoshi YoshinagaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Fumihiko IshimaruJapanese Red Cross Blood Service Headquarters, Tokyo, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Junya KandaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Funding

Japan Society for the Promotion of Science 25K11660
6 · The paper itself

Abstract

Outcomes of allogeneic hematopoietic stem cell transplantation are significantly influenced by conditioning regimens and graft-versus-host disease (GVHD) prophylaxis. Previous studies comparing matched-related donor (MRD) and umbilical cord blood (UCB) transplantation included patients with heterogeneous conditioning regimens and GVHD prophylaxis, potentially obscuring the true effects of donor type. We retrospectively compared outcomes of MRD (n = 1335) and UCB (n = 1097) transplantation performed with conditioning regimens and GVHD prophylaxis considered appropriate for cyclophosphamide/total body irradiation-based transplantation. Multivariable analysis revealed better relapse-free survival (RFS) for UCB than MRD in acute myeloid leukemia (hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.65-0.99; P = 0.04) and lymphoma (HR: 0.61; 95% CI: 0.37-0.997; P = 0.04). In contrast, RFS was similar between MRD and UCB in acute lymphoblastic leukemia (HR: 0.97; 95% CI: 0.79-1.18; P = 0.74) and worse for UCB in myelodysplastic syndrome (HR: 1.66; 95% CI: 1.09-2.52; P = 0.01). These findings suggest that, when appropriate regimens are used, UCB may perform more favorably than MRD depending on disease type. Further validation in independent registry studies is warranted.

Indexed as

Cord Blood Stem Cell TransplantationTissue DonorsAdolescentAdultAgedDisease-Free SurvivalFemaleFetal BloodGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesRetrospective StudiesAllogeneic hematopoietic stem cell transplantationDonor typeMatched-related donorUmbilical cord blood

Identifiers

PMID41926020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.